Jammu: India has summoned the Charge d’Affaires of the Pakistan High Commission and lodged a strong protest over the killing of three civilians including a child in an unprovoked ceasefire violation by Pakistani forces in Krishna Ghati sector of Jammu and Kashmir, the Ministry of External Affairs (MEA) said.
It said India strongly condemned the Pakistani action that took place on Friday night.
Those who were killed belonged to a single family, the government said, adding a child was also injured in the unprovoked firing.
“India condemns, in the strongest terms, the deliberate targeting of innocent civilians by Pakistan forces. This year alone, 21 Indians have been killed and 94 injured in over 2,711 unprovoked ceasefire violations by Pakistani forces,” the MEA said.
“India also protested Pakistan’s continued support to cross border terrorist infiltration into India, including supporting cover fire provided by Pakistani forces,” it said in a statement.
The MEA said Pakistan was called upon to adhere to the 2003 ceasefire understanding for maintaining peace and tranquillity along the Line of Control and the International Boundary.
AIIMS to begin Covid vaccine human trial from next week
In a major development, AIIMS Delhi will begin human trials of India’s first indigenous Covid-19 vaccine, Covaxin, from next week on 100 healthy volunteers aged between 18 and 55.
The volunteers will be kept under observation for a period of nearly 150 days. Covaxin is developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR) and the National Institute of Virology (NIV).
According to Bharat Biotech, the Phase 1 clinical trial for Covaxin has been initiated across the country from July 15 onwards, and this is a randomised, double-blind, placebo-controlled clinical trial on 375 volunteers across the country.
Speaking to IANS, Sanjay Rai, Professor of Community Medicine and Principal Investigator of Covid-19 vaccine trial at AIIMS, said: “We will begin human trials of India’s first indigenous vaccine, Covaxin, on 100 healthy volunteers aged between 18 and 55 years. We will ensure that none of the volunteers have any comorbidities. AIIMS will conduct trials on 100 volunteers out of a total of 375 persons.”
AIIMS has also set up a dedicated email and phone number for the volunteers to register themselves for this project. The volunteers will have to undergo tests, which include Covid-19 test and also tests for other comorbidities. If found healthy, they will be administered the vaccine.